Key Takeaways Roche announced plans to acquire Poseida Therapeutics for about $1 billion. Merck, AstraZeneca and Novartis ...

The following is a summary of “High 11-ketotestosterone linked to shorter time to castration resistance in recurrent ...

Truqap combination showed a statistically and clinically meaningful improvement in radiographic progression-free survival for ...

Diet is increasingly seen as a modifiable risk factor in prostate cancer. Recent studies have shown that ...

Data from a late-stage study shows that treatment with a three-drug combo involving AZN's Truqap benefits patients with an ...

Truqap’s positive clinical data comes after it failed a late-stage study in metastatic triple-negative breast cancer. It ...

The CAPItello-281 trial aimed to assess the safety and efficacy of Truqap in combination with abiraterone and ADT.

The FDA will review an application to consider potential approval of Nubeqa plus androgen deprivation therapy for metastatic ...

AstraZeneca (AZN) reported positive results from a Phase 3 study of its drug Truqap in the treatment of a certain type of ...

Patients with PTEN-deficient prostate cancer showed improvement in progression-free survival on Truqap plus standard therapy compared to standard therapy alone.

Investigators explored the role of treatment intensification with androgen receptor pathway inhibitors in patients with high-risk localized prostate cancer.

Results from the CAPItello-281 Phase III trial showed that AstraZeneca’s (AZN) Truqap in combination with abiraterone and androgen deprivation ...